文献速递中医内科中药与中成药合理使用

加味四妙勇安汤改善ACS大鼠模型的整合化学组成、转录组学与网络药理学机制研究

Integrated chemical composition, transcriptomics, and network pharmacology to reveal the mechanism of Jia-Wei-Si-Miao-Yong-An Decoction in ACS model rats.
PubMed 文献 · Phytomedicine · 2025-07-02

本研究采用UPLC-QE-Orbitrap-MS鉴定加味四妙勇安汤(HJ11)的化学成分及入血成分,结合ACS大鼠模型转录组学与网络药理学预测作用靶点,并通过大鼠及LPS诱导内皮细胞实验验证。结果显示HJ11可能通过调控DDAH/ADMA/NO通路、减轻炎症与氧化应激发挥抗ACS的多靶点作用。

要点

  • HJ11可能通过调控DDAH/ADMA/NO通路改善内皮功能。
  • HJ11可减轻炎症诱导的氧化应激,降低ADMA水平。
  • HJ11调节eNOS水平,体现多靶点抗ACS机制。

核心结论

  • HJ11通过DDAH/ADMA/NO通路、减轻炎症和氧化应激发挥抗ACS的综合多靶点机制。

研究设计与样本

  • 基于UPLC-QE-Orbitrap-MS鉴定HJ11化学成分及入血成分,结合ACS大鼠模型转录组学与网络药理学分析,再用ACS大鼠模型和LPS诱导内皮细胞通过RT-PCR、Western blot、免疫荧光等验证。

主要发现

  • UPLC-QE-Orbitrap-MS初步鉴定HJ11汤剂中212种化学成分,其中49种与入血成分一致,包括有机酸、黄酮类和氨基酸。
  • 网络药理学分析提示HJ11可能通过炎症反应、氧化应激等多种机制改善ACS。
  • 实验验证发现HJ11调节eNOS水平,减少炎症诱导的氧化应激,降低ADMA水平并调控DDAH/ADMA/NO通路。

临床怎么用

  • HJ11的多靶点机制提示其可作为ACS的潜在整体治疗策略,但临床转化需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Acute Coronary Syndrome (ACS), as the most critical pathological type of coronary atherosclerotic heart disease, has a high morbidity and lethality, and the long-term treatment of modern medicine is still faced with the problems of restenosis, microcirculation obstruction and drug resistance. The addition of Traditional Chinese Medicine provides new ideas for ACS treatment. Our previous study found that Jia-Wei-Si-Miao-Yong-An decoction (HJ11) can improve the inflammatory response and cardiac function in ACS. However, its mechanism of action needs to be studied in depth. PURPOSE: This study aimed to combine transcriptomics and network pharmacology based on the study of HJ11 components, elucidate the mechanism of HJ11 in ameliorating ACS by experimental validation. METHODS: UPLC-QE-Orbitrap-MS was utilized for the preliminary identification of HJ11 decoction and blood-entry components. And based on the results of the compositional studies, combining with the transcriptomic results of ACS rat model, network pharmacological analysis was performed to identify the potential targets of HJ11 action. The ACS rat model and LPS-induced endothelial cells were further used for experimental validation using RT-PCR, Western blot techniques, immunofluorescence and other techniques. RESULTS: UPLC-QE-Orbitrap-MS analysis preliminarily identified 212 chemical constituents of HJ11 decoction, of which 49 were consistent with the blood-entered constituents, including organic acids, flavonoids, and amino acids. Combining the compositional studies and transcriptomics results with network pharmacology analysis, HJ11 may ameliorate ACS through various mechanisms (including inflammatory response, oxidative stress, etc.). We verified the mechanisms using rats and endothelial cells and found that HJ11 modulates eNOS levels; reduces inflammation-induced oxidative stress; reduces ADMA levels, which are closely related to inflammation, oxidative stress, and endothelial function and modulates DDAH/ADMA/NO pathway. CONCLUSION: HJ11 exhibits a comprehensive multi-target mechanism against ACS, acting through the DDAH/ADMA/NO pathway, reducing inflammation, and attenuating oxidative stress. These findings highlight HJ11 as a promising, holistic therapeutic strategy for ACS, illustrating the potential of Chinese herbal formulas in addressing complex cardiovascular diseases.

来源:Phytomedicine,查看原文。版权归原作者所有。

引用

  1. Zhao N, Dang M, Sun Y, et al. Integrated chemical composition, transcriptomics, and network pharmacology to reveal the mechanism of Jia-Wei-Si-Miao-Yong-An Decoction in ACS model rats. Phytomedicine. 2025. PMID: 40645073. doi:10.1016/j.phymed.2025.157027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。